New drug combo aims to protect heart transplants
NCT ID NCT03292861
First seen Jan 19, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tests whether adding the drug Thymoglobulin to standard anti-rejection medicines can prevent heart transplant complications. About 60 people receiving their first heart transplant will take part. Half will get Thymoglobulin for 5 days after surgery, and all will be monitored for a year to see if their new hearts stay healthier.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States
Conditions
Explore the condition pages connected to this study.